A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer

Collins, K.K. The diabetes-cancer link. Diabetes Spectr., 2014, 27(4), 276-280.
[http://dx.doi.org/10.2337/diaspect.27.4.276] [PMID: 25647050]

Ferroni, P.; Riondino, S.; Buonomo, O.; Palmirotta, R.; Guadagni, F.; Roselli, M. Type 2 diabetes and breast cancer: the interplay between impaired glucose metabolism and oxidant stress. Oxid. Med. Cell. Longev., 2015, 2015, 183928.
[http://dx.doi.org/10.1155/2015/183928] [PMID: 26171112]

Samuel, S.M.; Varghese, E.; Varghese, S.; Büsselberg, D. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treat. Rev., 2018, 70, 98-111.
[http://dx.doi.org/10.1016/j.ctrv.2018.08.004] [PMID: 30130687]

Dai, X.; Li, T.; Bai, Z.; Yang, Y.; Liu, X.; Zhan, J.; Shi, B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am. J. Cancer Res., 2015, 5(10), 2929-2943.
[PMID: 26693050]

Feng, Y.; Spezia, M.; Huang, S.; Yuan, C.; Zeng, Z.; Zhang, L.; Ji, X.; Liu, W.; Huang, B.; Luo, W.; Liu, B.; Lei, Y.; Du, S.; Vuppalapati, A.; Luu, H.H.; Haydon, R.C.; He, T.C.; Ren, G. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis., 2018, 5(2), 77-106.
[http://dx.doi.org/10.1016/j.gendis.2018.05.001] [PMID: 30258937]

Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X. E LP, Borresen-Dale AL, Brown PO and Botstein D. Molecular portraits of human breast tumors. Nature, 2000, 406, 747-752.
[http://dx.doi.org/10.1038/35021093] [PMID: 10963602]

Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Lønning, P.E.; Børresen-Dale, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 2001, 98(19), 10869-10874.
[http://dx.doi.org/10.1073/pnas.191367098] [PMID: 11553815]

Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C.M.; Lønning, P.E.; Brown, P.O.; Børresen-Dale, A.L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8418-8423.
[http://dx.doi.org/10.1073/pnas.0932692100] [PMID: 12829800]

Abd El-Rehim, D.M.; Pinder, S.E.; Paish, C.E.; Bell, J.; Blamey, R.W.; Robertson, J.F.; Nicholson, R.I.; Ellis, I.O. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol., 2004, 203(2), 661-671.
[http://dx.doi.org/10.1002/path.1559] [PMID: 15141381]

Brenton, J.D.; Carey, L.A.; Ahmed, A.A.; Caldas, C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol., 2005, 23(29), 7350-7360.
[http://dx.doi.org/10.1200/JCO.2005.03.3845] [PMID: 16145060]

Miller, K.D.; Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Pegram, M.D.; Eisenberg, P.D.; Collier, M.; Adams, B.J.; Baum, C.M. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastaticbreast cancer (MBC). J. Clin. Oncol., 2005, 23, 563-563.
[http://dx.doi.org/10.1200/jco.2005.23.16_suppl.563]

Abbas, S.; Linseisen, J.; Slanger, T.; Kropp, S.; Mutschelknauss, E.J.; Flesch-Janys, D.; Chang-Claude, J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer- results of a large case-control study. Carcinogenesis, 2008, 29(1), 93-99.
[http://dx.doi.org/10.1093/carcin/bgm240] [PMID: 17974532]

Morikawa, A.; Henry, N.L. Palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res., 2015, 21(16), 3591-3596.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0390] [PMID: 26100274]

Carey, L.A.; Perou, C.M.; Livasy, C.A.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; Deming, S.L.; Geradts, J.; Cheang, M.C.; Nielsen, T.O.; Moorman, P.G.; Earp, H.S.; Millikan, R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21), 2492-2502.
[http://dx.doi.org/10.1001/jama.295.21.2492] [PMID: 16757721]

Rouzier, R.; Perou, C.M.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J.S.; Hortobagyi, G.N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res., 2005, 11(16), 5678-5685.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-2421] [PMID: 16115903]

Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li, P.; Monia, B.P.; Nguyen, N.T.; Hortobagyi, G.N.; Hung, M.C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6(2), 117-127.
[http://dx.doi.org/10.1016/j.ccr.2004.06.022] [PMID: 15324695]

Tripathy, D.; Hassan, S.; Verma, S.; Gurnani, P.; Nandi, A.; Rosenblatt, K. Phenotypic and proteomic alterations of acquired trastuzumab resistance. J. Clin. Oncol., 2005, 23, 3121-3121.
[http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3121]

Cancello, G.; Montagna, E.; D’Agostino, D.; Giuliano, M.; Giordano, A.; Di Lorenzo, G.; Plaitano, M.; De Placido, S.; De Laurentiis, M. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res., 2008, 10(4), R60.
[http://dx.doi.org/10.1186/bcr2119] [PMID: 18631394]

Sotiriou, C.; Neo, S.Y.; McShane, L.M.; Korn, E.L.; Long, P.M.; Jazaeri, A.; Martiat, P.; Fox, S.B.; Harris, A.L.; Liu, E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA, 2003, 100(18), 10393-10398.
[http://dx.doi.org/10.1073/pnas.1732912100] [PMID: 12917485]

O’Brien, K.M.; Cole, S.R.; Tse, C.K.; Perou, C.M.; Carey, L.A.; Foulkes, W.D.; Dressler, L.G.; Geradts, J.; Millikan, R.C. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin. Cancer Res., 2010, 16(24), 6100-6110.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-1533] [PMID: 21169259]

Fan, C.; Oh, D.S.; Wessels, L.; Weigelt, B.; Nuyten, D.S.; Nobel, A.B.; van’t Veer, L.J.; Perou, C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med., 2006, 355(6), 560-569.
[http://dx.doi.org/10.1056/NEJMoa052933] [PMID: 16899776]

Swenson, R.R.; Rizzo, C.J.; Brown, L.K.; Payne, N.; DiClemente, R.J.; Salazar, L.F.; Vanable, P.A.; Carey, M.P.; Valois, R.F.; Romer, D.; Hennessy, M. Prevalence and correlates of HIV testing among sexually active African American adolescents in 4 US cities. Sex. Transm. Dis., 2009, 36(9), 584-591.
[http://dx.doi.org/10.1097/OLQ.0b013e3181b4704c] [PMID: 19661840]

Ho-Yen, C.; Bowen, R.L.; Jones, J. Characterization of basal-like breast cancer: an update. Diagn. Histopathol., 2012, 18, 104-111.
[http://dx.doi.org/10.1016/j.mpdhp.2011.12.002]

Jääskeläinen, A.; Roininen, N.; Karihtala, P.; Jukkola, A. High parity predicts poor outcomes in patients with luminal b-like (HER2 negative) early breast cancer: a prospective finnish single-center study. Front. Oncol., 2020, 10, 1470.
[http://dx.doi.org/10.3389/fonc.2020.01470] [PMID: 32923400]

Rakha, E.A.; Putti, T.C.; Abd El-Rehim, D.M.; Paish, C.; Green, A.R.; Powe, D.G.; Lee, A.H.; Robertson, J.F.; Ellis, I.O. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol., 2006, 208(4), 495-506.
[http://dx.doi.org/10.1002/path.1916] [PMID: 16429394]

Jääskeläinen, A.; Soini, Y.; Jukkola-Vuorinen, A.; Auvinen, P.; Haapasaari, K.M.; Karihtala, P. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. BMC Cancer, 2018, 18(1), 223.
[http://dx.doi.org/10.1186/s12885-018-4141-z] [PMID: 29482498]

Rouzier, R.; Anderson, K.; Hess, K.R. Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium, San Antonio, TX2004.

Chang, H.Y.; Nuyten, D.S.; Sneddon, J.B.; Hastie, T.; Tibshirani, R.; Sørlie, T.; Dai, H.; He, Y.D.; van’t Veer, L.J.; Bartelink, H.; van de Rijn, M.; Brown, P.O.; van de Vijver, M.J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA, 2005, 102(10), 3738-3743.
[http://dx.doi.org/10.1073/pnas.0409462102] [PMID: 15701700]

Smid, M.; Wang, Y.; Zhang, Y.; Sieuwerts, A.M.; Yu, J.; Klijn, J.G.; Foekens, J.A.; Martens, J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res., 2008, 68(9), 3108-3114.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5644] [PMID: 18451135]

Boyle, P.; Boniol, M.; Koechlin, A.; Robertson, C.; Valentini, F.; Coppens, K.; Fairley, L.L.; Boniol, M.; Zheng, T.; Zhang, Y.; Pasterk, M.; Smans, M.; Curado, M.P.; Mullie, P.; Gandini, S.; Bota, M.; Bolli, G.B.; Rosenstock, J.; Autier, P. Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer, 2012, 107(9), 1608-1617.
[http://dx.doi.org/10.1038/bjc.2012.414] [PMID: 22996614]

Hardefeldt, P.J.; Edirimanne, S.; Eslick, G.D. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr. Relat. Cancer, 2012, 19(6), 793-803.
[http://dx.doi.org/10.1530/ERC-12-0242] [PMID: 23035011]

Larsson, S.C.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer, 2007, 121(4), 856-862.
[http://dx.doi.org/10.1002/ijc.22717] [PMID: 17397032]

Carstensen, B.; Jørgensen, M.E.; Friis, S. The epidemiology of diabetes and cancer. Curr. Diab. Rep., 2014, 14(10), 535.
[http://dx.doi.org/10.1007/s11892-014-0535-8] [PMID: 25156543]

Memon, A.A.; Bennet, L.; Zöller, B.; Wang, X.; Palmer, K.; Sundquist, K.; Sundquist, J. Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance. J. Diabetes, 2015, 7(3), 369-377.
[http://dx.doi.org/10.1111/1753-0407.12184] [PMID: 24981162]

Fernández-Real, J.M.; Menendez, J.A.; Frühbeck, G.; Moreno-Navarrete, J.M.; Vazquez-Martín, A.; Ricart, W. Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. Nutr. Metab. (Lond.), 2010, 7, 14-21.
[http://dx.doi.org/10.1186/1743-7075-7-14] [PMID: 20184722]

Kang, C.; LeRoith, D.; Gallagher, E.J. Diabetes, obesity, and breast cancer. Endocrinology, 2018, 159(11), 3801-3812.
[http://dx.doi.org/10.1210/en.2018-00574] [PMID: 30215698]

Ray, A.; Alalem, M.; Ray, B.K. Insulin signaling network in cancer. Indian J. Biochem. Biophys., 2014, 51(6), 493-498.
[PMID: 25823221]

Luque, R.M.; López-Sánchez, L.M.; Villa-Osaba, A.; Luque, I.M.; Santos-Romero, A.L.; Yubero-Serrano, E.M.; Cara-García, M.; Álvarez-Benito, M.; López-Mirand A, J.; Gahete, M.D.; Castaño, J.P. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. Oncotarget, 2017, 8(46), 81462-81474.
[http://dx.doi.org/10.18632/oncotarget.20399] [PMID: 29113405]

Bronsveld, H.K.; Jensen, V.; Vahl, P.; De Bruin, M.L.; Cornelissen, S.; Sanders, J.; Auvinen, A.; Haukka, J.; Andersen, M.; Vestergaard, P.; Schmidt, M.K. Diabetes and Breast Cancer Subtypes. PLoS One, 2017, 12(1), e0170084.
[http://dx.doi.org/10.1371/journal.pone.0170084] [PMID: 28076434]

Suba, Z. Interplay between insulin resistance and estrogen deficiency as co- activators in carcinogenesis. Pathol. Oncol. Res., 2012, 18(2), 123-133.
[http://dx.doi.org/10.1007/s12253-011-9466-8] [PMID: 21984197]

Johnson, J.A.; Gale, E.A. Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes, 2010, 59(5), 1129-1131.
[http://dx.doi.org/10.2337/db10-0334] [PMID: 20427699]

Orgel, E.; Mittelman, S.D. The links between insulin resistance, diabetes, and cancer. Curr. Diab. Rep., 2013, 13(2), 213-222.
[http://dx.doi.org/10.1007/s11892-012-0356-6] [PMID: 23271574]

Tseng, C.H. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer, 2015, 15, 846.
[http://dx.doi.org/10.1186/s12885-015-1876-7] [PMID: 26537234]

Starup-Linde, J.; Karlstad, O.; Eriksen, S.A.; Vestergaard, P.; Bronsveld, H.K.; de Vries, F.; Andersen, M.; Auvinen, A.; Haukka, J.; Hjellvik, V.; Bazelier, M.T.; Boer, Ad.; Furu, K.; De Bruin, M.L. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. Curr. Drug Saf., 2013, 8(5), 296-332.
[http://dx.doi.org/10.2174/15748863113086660071] [PMID: 24215312]

Liao, S.; Li, J.; Wei, W.; Wang, L.; Zhang, Y.; Li, J.; Wang, C.; Sun, S. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac. J. Cancer Prev., 2011, 12(4), 1061-1065.
[PMID: 21790252]

Xue, F.; Michels, K.B. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am. J. Clin. Nutr., 2007, 86(3), s823-s835.
[http://dx.doi.org/10.1093/ajcn/86.3.823S] [PMID: 18265476]

Peairs, K.S.; Barone, B.B.; Snyder, C.F.; Yeh, H.C.; Stein, K.B.; Derr, R.L.; Brancati, F.L.; Wolff, A.C. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J. Clin. Oncol., 2011, 29(1), 40-46.
[http://dx.doi.org/10.1200/JCO.2009.27.3011] [PMID: 21115865]

Hou, G.; Zhang, S.; Zhang, X.; Wang, P.; Hao, X.; Zhang, J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res. Treat., 2013, 137(3), 807-816.
[http://dx.doi.org/10.1007/s10549-012-2404-y] [PMID: 23292119]

Renehan, A.G.; Yeh, H.C.; Johnson, J.A.; Wild, S.H.; Gale, E.A.M.; Møller, H. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia, 2012, 55(6), 1619-1632.
[http://dx.doi.org/10.1007/s00125-012-2526-0] [PMID: 22476948]

Liao, S.; Li, J.; Wang, L.; Zhang, Y.; Wang, C.; Hu, M.; Ma, B.; Wang, G.; Sun, S. Type 2 diabetes mellitus and characteristics of breast cancer in China. Asian Pac. J. Cancer Prev., 2010, 11(4), 933-937.
[PMID: 21133604]

Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Trudeau, M.E.; Koo, J.; Madarnas, Y.; Hartwick, W.; Hoffman, B.; Hood, N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol., 2002, 20(1), 42-51.
[http://dx.doi.org/10.1200/JCO.2002.20.1.42] [PMID: 11773152]

Rao Kondapally Seshasai, S.; Kaptoge, S.; Thompson, A.; Di Angelantonio, E.; Gao, P.; Sarwar, N.; Whincup, P.H.; Mukamal, K.J.; Gillum, R.F.; Holme, I.; Njølstad, I.; Fletcher, A.; Nilsson, P.; Lewington, S.; Collins, R.; Gudnason, V.; Thompson, S.G.; Sattar, N.; Selvin, E.; Hu, F.B.; Danesh, J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med., 2011, 364(9), 829-841.
[http://dx.doi.org/10.1056/NEJMoa1008862] [PMID: 21366474]

Zhou, X.H.; Qiao, Q.; Zethelius, B.; Pyörälä, K.; Söderberg, S.; Pajak, A.; Stehouwer, C.D.A.; Heine, R.J.; Jousilahti, P.; Ruotolo, G.; Nilsson, P.M.; Calori, G.; Tuomilehto, J. Diabetes, prediabetes and cancer mortality. Diabetologia, 2010, 53(9), 1867-1876.
[http://dx.doi.org/10.1007/s00125-010-1796-7] [PMID: 20490448]

Yang, X.R.; Chang-Claude, J.; Goode, E.L.; Couch, F.J.; Nevanlinna, H.; Milne, R.L.; Gaudet, M.; Schmidt, M.K.; Broeks, A.; Cox, A.; Fasching, P.A.; Hein, R.; Spurdle, A.B.; Blows, F.; Driver, K.; Flesch-Janys, D.; Heinz, J.; Sinn, P.; Vrieling, A.; Heikkinen, T.; Aittomäki, K.; Heikkilä, P.; Blomqvist, C.; Lissowska, J.; Peplonska, B.; Chanock, S.; Figueroa, J.; Brinton, L.; Hall, P.; Czene, K.; Humphreys, K.; Darabi, H.; Liu, J.; Van ’t Veer, L.J.; van Leeuwen, F.E.; Andrulis, I.L.; Glendon, G.; Knight, J.A.; Mulligan, A.M.; O’Malley, F.P.; Weerasooriya, N.; John, E.M.; Beckmann, M.W.; Hartmann, A.; Weihbrecht, S.B.; Wachter, D.L.; Jud, S.M.; Loehberg, C.R.; Baglietto, L.; English, D.R.; Giles, G.G.; McLean, C.A.; Severi, G.; Lambrechts, D.; Vandorpe, T.; Weltens, C.; Paridaens, R.; Smeets, A.; Neven, P.; Wildiers, H.; Wang, X.; Olson, J.E.; Cafourek, V.; Fredericksen, Z.; Kosel, M.; Vachon, C.; Cramp, H.E.; Connley, D.; Cross, S.S.; Balasubramanian, S.P.; Reed, M.W.; Dörk, T.; Bremer, M.; Meyer, A.; Karstens, J.H.; Ay, A.; Park-Simon, T.W.; Hillemanns, P.; Arias Pérez, J.I.; Menéndez Rodríguez, P.; Zamora, P.; Benítez, J.; Ko, Y.D.; Fischer, H.P.; Hamann, U.; Pesch, B.; Brüning, T.; Justenhoven, C.; Brauch, H.; Eccles, D.M.; Tapper, W.J.; Gerty, S.M.; Sawyer, E.J.; Tomlinson, I.P.; Jones, A.; Kerin, M.; Miller, N.; McInerney, N.; Anton-Culver, H.; Ziogas, A.; Shen, C.Y.; Hsiung, C.N.; Wu, P.E.; Yang, S.L.; Yu, J.C.; Chen, S.T.; Hsu, G.C.; Haiman, C.A.; Henderson, B.E.; Le Marchand, L.; Kolonel, L.N.; Lindblom, A.; Margolin, S.; Jakubowska, A.; Lubiński, J.; Huzarski, T.; Byrski, T.; Górski, B.; Gronwald, J.; Hooning, M.J.; Hollestelle, A.; van den Ouweland, A.M.; Jager, A.; Kriege, M.; Tilanus-Linthorst, M.M.; Collée, M.; Wang-Gohrke, S.; Pylkäs, K.; Jukkola-Vuorinen, A.; Mononen, K.; Grip, M.; Hirvikoski, P.; Winqvist, R.; Mannermaa, A.; Kosma, V.M.; Kauppinen, J.; Kataja, V.; Auvinen, P.; Soini, Y.; Sironen, R.; Bojesen, S.E.; Ørsted, D.D.; Kaur-Knudsen, D.; Flyger, H.; Nordestgaard, B.G.; Holland, H.; Chenevix-Trench, G.; Manoukian, S.; Barile, M.; Radice, P.; Hankinson, S.E.; Hunter, D.J.; Tamimi, R.; Sangrajrang, S.; Brennan, P.; McKay, J.; Odefrey, F.; Gaborieau, V.; Devilee, P.; Huijts, P.E.; Tollenaar, R.A.; Seynaeve, C.; Dite, G.S.; Apicella, C.; Hopper, J.L.; Hammet, F.; Tsimiklis, H.; Smith, L.D.; Southey, M.C.; Humphreys, M.K.; Easton, D.; Pharoah, P.; Sherman, M.E.; Garcia-Closas, M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J. Natl. Cancer Inst., 2011, 103(3), 250-263.
[http://dx.doi.org/10.1093/jnci/djq526] [PMID: 21191117]

Phipps, A.I.; Buist, D.S.; Malone, K.E.; Barlow, W.E.; Porter, P.L.; Kerlikowske, K.; O’Meara, E.S.; Li, C.I. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann. Epidemiol., 2012, 22(5), 340-348.
[http://dx.doi.org/10.1016/j.annepidem.2012.02.002] [PMID: 22366170]

Rose, D.P.; Vona-Davis, L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr. Relat. Cancer, 2012, 19(6), R225-R241.
[http://dx.doi.org/10.1530/ERC-12-0203] [PMID: 22936542]

Gapstur, S.M.; Patel, A.V.; Diver, W.R.; Hildebrand, J.S.; Gaudet, M.M.; Jacobs, E.J.; Campbell, P.T. Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort. Cancer Epidemiol. Biomarkers Prev., 2012, 21(11), 2000-2005.
[http://dx.doi.org/10.1158/1055-9965.EPI-12-0867] [PMID: 22941335]

Wotton, C.J.; Yeates, D.G.; Goldacre, M.J. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia, 2011, 54(3), 527-534.
[http://dx.doi.org/10.1007/s00125-010-1987-2] [PMID: 21116605]

IDF Diabetes Atlas- 8th Edition, 2017. Available from: http://www.diabetesatlas.org/resources/2017-atlas.html

Aronoff, S.L.; Berkowitz, K.; Shreiner, B.; Want, L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr., 2004, 17, 183-190.
[http://dx.doi.org/10.2337/diaspect.17.3.183]

Heuson, J.C.; Coune, A.; Heimann, R. Cell proliferation induced by insulin in organ culture of rat mammary carcinoma. Exp. Cell Res., 1967, 45(2), 351-360.
[http://dx.doi.org/10.1016/0014-4827(67)90185-1] [PMID: 6021927]

Osborne, C.K.; Bolan, G.; Monaco, M.E.; Lippman, M.E. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc. Natl. Acad. Sci. USA, 1976, 73(12), 4536-4540.
[http://dx.doi.org/10.1073/pnas.73.12.4536] [PMID: 1070004]

van der Burg, B.; Rutteman, G.R.; Blankenstein, M.A.; de Laat, S.W.; van Zoelen, E.J. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J. Cell. Physiol., 1988, 134(1), 101-108.
[http://dx.doi.org/10.1002/jcp.1041340112] [PMID: 3275677]

Maassen, J.A.; Krans, H.M.; Möller, W. The effect of insulin, serum and dexamethasone on mRNA levels for the insulin receptor in the human lymphoblastoic cell line IM-9. Biochim. Biophys. Acta, 1987, 930(1), 72-78.
[http://dx.doi.org/10.1016/0167-4889(87)90157-1] [PMID: 3304429]

Okabayashi, Y.; Maddux, B.A.; McDonald, A.R.; Logsdon, C.D.; Williams, J.A.; Goldfine, I.D. Mechanisms of insulin-induced insulin-receptor downregulation. Decrease of receptor biosynthesis and mRNA levels. Diabetes, 1989, 38(2), 182-187.
[http://dx.doi.org/10.2337/diab.38.2.182] [PMID: 2644141]

Milazzo, G.; Giorgino, F.; Damante, G.; Sung, C.; Stampfer, M.R.; Vigneri, R.; Goldfine, I.D.; Belfiore, A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res., 1992, 52(14), 3924-3930.
[PMID: 1617668]

Belfiore, A.; Malaguarnera, R. Insulin receptor and cancer. Endocr. Relat. Cancer, 2011, 18(4), R125-R147.
[http://dx.doi.org/10.1530/ERC-11-0074] [PMID: 21606157]

Giorgino, F.; Belfiore, A.; Milazzo, G.; Costantino, A.; Maddux, B.; Whittaker, J.; Goldfine, I.D.; Vigneri, R. Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol. Endocrinol., 1991, 5(3), 452-459.
[http://dx.doi.org/10.1210/mend-5-3-452] [PMID: 1653897]

Rose, P.P.; Carroll, J.M.; Carroll, P.A.; DeFilippis, V.R.; Lagunoff, M.; Moses, A.V.; Roberts, C.T., Jr; Früh, K. The insulin receptor is essential for virus-induced tumorigenesis of Kaposi’s sarcoma. Oncogene, 2007, 26(14), 1995-2005.
[http://dx.doi.org/10.1038/sj.onc.1210006] [PMID: 17001305]

Mathieu, M.C.; Clark, G.M.; Allred, D.C.; Goldfine, I.D.; Vigneri, R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc. Assoc. Am. Physicians, 1997, 109(6), 565-571.
[PMID: 9394418]

Law, J.H.; Habibi, G.; Hu, K.; Masoudi, H.; Wang, M.Y.; Stratford, A.L.; Park, E.; Gee, J.M.; Finlay, P.; Jones, H.E.; Nicholson, R.I.; Carboni, J.; Gottardis, M.; Pollak, M.; Dunn, S.E. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res., 2008, 68(24), 10238-10246.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2755] [PMID: 19074892]

Osborne, C.K.; Monaco, M.E.; Lippman, M.E.; Kahn, C.R. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res., 1978, 38(1), 94-102.
[PMID: 22400]

Mountjoy, K.G.; Holdaway, I.M.; Finlay, G.J. Insulin receptor regulation in cultured human tumor cells. Cancer Res., 1983, 43(10), 4537-4542.
[PMID: 6349794]

Loeper, S.; Ezzat, S. Acromegaly: re-thinking the cancer risk. Rev. Endocr. Metab. Disord., 2008, 9(1), 41-58.
[http://dx.doi.org/10.1007/s11154-007-9063-z] [PMID: 18157698]

Rinaldi, S.; Cleveland, R.; Norat, T.; Biessy, C.; Rohrmann, S.; Linseisen, J.; Boeing, H.; Pischon, T.; Panico, S.; Agnoli, C.; Palli, D.; Tumino, R.; Vineis, P.; Peeters, P.H.; van Gils, C.H.; Bueno-de-Mesquita, B.H.; Vrieling, A.; Allen, N.E.; Roddam, A.; Bingham, S.; Khaw, K.T.; Manjer, J.; Borgquist, S.; Dumeaux, V.; Torhild Gram, I.; Lund, E.; Trichopoulou, A.; Makrygiannis, G.; Benetou, V.; Molina, E.; Donate Suárez, I.; Barricarte Gurrea, A.; Gonzalez, C.A.; Tormo, M.J.; Altzibar, J.M.; Olsen, A.; Tjonneland, A.; Grønbaek, H.; Overvad, K.; Clavel-Chapelon, F.; Boutron-Ruault, M.C.; Morois, S.; Slimani, N.; Boffetta, P.; Jenab, M.; Riboli, E.; Kaaks, R. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int. J. Cancer, 2010, 126(7), 1702-1715.
[http://dx.doi.org/10.1002/ijc.24927] [PMID: 19810099]

Huang, Y.F.; Shen, M.R.; Hsu, K.F.; Cheng, Y.M.; Chou, C.Y. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br. J. Cancer, 2008, 99(7), 1096-1102.
[http://dx.doi.org/10.1038/sj.bjc.6604661] [PMID: 18781172]

Wu, Y.; Yakar, S.; Zhao, L.; Hennighausen, L.; LeRoith, D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res., 2002, 62(4), 1030-1035.
[PMID: 11861378]

Wu, Y.; Cui, K.; Miyoshi, K.; Hennighausen, L.; Green, J.E.; Setser, J.; LeRoith, D.; Yakar, S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res., 2003, 63(15), 4384-4388.
[PMID: 12907608]

de Ostrovich, K.K.; Lambertz, I.; Colby, J.K.; Tian, J.; Rundhaug, J.E.; Johnston, D.; Conti, C.J.; DiGiovanni, J.; Fuchs-Young, R. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am. J. Pathol., 2008, 173(3), 824-834.
[http://dx.doi.org/10.2353/ajpath.2008.071005] [PMID: 18688034]

Bhaskar, P.T.; Hay, N. The two TORCs and Akt. Dev. Cell, 2007, 12(4), 487-502.
[http://dx.doi.org/10.1016/j.devcel.2007.03.020] [PMID: 17419990]

Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12(1), 9-22.
[http://dx.doi.org/10.1016/j.ccr.2007.05.008] [PMID: 17613433]

Efeyan, A.; Sabatini, D.M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol., 2010, 22(2), 169-176.
[http://dx.doi.org/10.1016/j.ceb.2009.10.007] [PMID: 19945836]

Vogt, P.K. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol. Med., 2001, 7(11), 482-484.
[http://dx.doi.org/10.1016/S1471-4914(01)02161-X] [PMID: 11689313]

Kenerson, H.L.; Aicher, L.D.; True, L.D.; Yeung, R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res., 2002, 62(20), 5645-5650.
[PMID: 12384518]

Gao, N.; Flynn, D.C.; Zhang, Z.; Zhong, X.S.; Walker, V.; Liu, K.J.; Shi, X.; Jiang, B.H. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol., 2004, 287(2), C281-C291.
[http://dx.doi.org/10.1152/ajpcell.00422.2003] [PMID: 15028555]

Kremer, C.L.; Klein, R.R.; Mendelson, J.; Browne, W.; Samadzedeh, L.K.; Vanpatten, K.; Highstrom, L.; Pestano, G.A.; Nagle, R.B. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate, 2006, 66(11), 1203-1212.
[http://dx.doi.org/10.1002/pros.20410] [PMID: 16652388]

No, J.H.; Jeon, Y.T.; Park, I.A.; Kang, D.; Kim, J.W.; Park, N.H.; Kang, S.B.; Song, Y.S. Expression of mTOR protein and its clinical significance in endometrial cancer. Med. Sci. Monit., 2009, 15(10), BR301-BR305.
[PMID: 19789507]

Yu, G.; Wang, J.; Chen, Y.; Wang, X.; Pan, J.; Li, G.; Jia, Z.; Li, Q.; Yao, J.C.; Xie, K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin. Cancer Res., 2009, 15(5), 1821-1829.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2138] [PMID: 19223493]

Pópulo, H.; Lopes, J.M.; Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci., 2012, 13(2), 1886-1918.
[http://dx.doi.org/10.3390/ijms13021886] [PMID: 22408430]

Alqurashi, N.; Gopalan, V.; Smith, R.A.; Lam, A.K. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers. Hum. Pathol., 2013, 44(10), 2089-2096.
[http://dx.doi.org/10.1016/j.humpath.2013.03.014] [PMID: 23773481]

Alvarez, M.; Roman, E.; Santos, E.S.; Raez, L.E. New targets for non-small-cell lung cancer therapy. Expert Rev. Anticancer Ther., 2007, 7(10), 1423-1437.
[http://dx.doi.org/10.1586/14737140.7.10.1423] [PMID: 17944567]

Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol., 2010, 28(6), 1075-1083.
[http://dx.doi.org/10.1200/JCO.2009.25.3641] [PMID: 20085938]

Dufour, M.; Dormond-Meuwly, A.; Demartines, N.; Dormond, O. Targeting the mammalian target of rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives. Cancers (Basel), 2011, 3(2), 2478-2500.
[http://dx.doi.org/10.3390/cancers3022478] [PMID: 24212820]

Burris, H.A., III Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother. Pharmacol., 2013, 71(4), 829-842.
[http://dx.doi.org/10.1007/s00280-012-2043-3] [PMID: 23377372]

Escudero, C.A.; Herlitz, K.; Troncoso, F.; Guevara, K.; Acurio, J.; Aguayo, C.; Godoy, A.S.; González, M. Pro-angiogenic role of insulin: from physiology to pathology. Front. Physiol., 2017, 8, 204.
[http://dx.doi.org/10.3389/fphys.2017.00204] [PMID: 28424632]

Treins, C.; Giorgetti-Peraldi, S.; Murdaca, J.; Semenza, G.L.; Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem., 2002, 277(31), 27975-27981.
[http://dx.doi.org/10.1074/jbc.M204152200] [PMID: 12032158]

Pilkis, S.J.; Granner, D.K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol., 1992, 54, 885-909.
[http://dx.doi.org/10.1146/annurev.ph.54.030192.004321] [PMID: 1562196]

Sutherland, C.; O’Brien, R.M.; Granner, D.K. New connections in the regulation of PEPCK gene expression by insulin. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1996, 351(1336), 191-199.
[http://dx.doi.org/10.1098/rstb.1996.0016] [PMID: 8650266]

Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001, 414(6865), 799-806.
[http://dx.doi.org/10.1038/414799a] [PMID: 11742412]

Masuda, S.; Chikuma, M.; Sasaki, R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res., 1997, 746(1-2), 63-70.
[http://dx.doi.org/10.1016/S0006-8993(96)01186-9] [PMID: 9037485]

Lu, M.; Amano, S.; Miyamoto, K.; Garland, R.; Keough, K.; Qin, W.; Adamis, A.P. Insulin-induced vascular endothelial growth factor expression in retina. Invest. Ophthalmol. Vis. Sci., 1999, 40(13), 3281-3286.
[PMID: 10586954]

Duh, E.; Aiello, L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes, 1999, 48(10), 1899-1906.
[http://dx.doi.org/10.2337/diabetes.48.10.1899] [PMID: 10512352]

Ricketts, H.T. Does hyperglycemia harm the diabetic patient? Med. Clin. North Am., 1947, 31, 267-277.
[http://dx.doi.org/10.1016/S0025-7125(16)35832-1] [PMID: 20293070]

Berry, M.G.; Helwig, F.C. Marked insulin resistance in diabetes mellitus. Am. J. Med., 1948, 4(6), 923-926.
[http://dx.doi.org/10.1016/0002-9343(48)90490-2] [PMID: 18860412]

Ahmed, A.; Khan, T.E.; Yasmeen, T.; Awan, S.; Islam, N. Metabolic syndrome in type 2 diabetes: comparison of WHO, modified ATPIII & IDF criteria. J. Pak. Med. Assoc., 2012, 62(6), 569-574.
[PMID: 22755342]

Aldhafiri, F.; Al-Nasser, A.; Al-Sugair, A.; Al-Mutairi, H.; Young, D.; Reilly, J.J. Obesity and metabolic syndrome in adolescent survivors of standard risk childhood acute lymphoblastic leukemia in Saudi Arabia. Pediatr. Blood Cancer, 2012, 59(1), 133-137.
[http://dx.doi.org/10.1002/pbc.24012] [PMID: 22162511]

Zhang, B.; Roth, R.A. Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin- like growth factor I receptor or the insulin receptor related receptor. Biochemistry, 1991, 30(21), 5113-5117.
[http://dx.doi.org/10.1021/bi00235a001] [PMID: 1645190]

Artim, S.C.; Mendrola, J.M.; Lemmon, M.A. Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem. J., 2012, 448(2), 213-220.
[http://dx.doi.org/10.1042/BJ20121365] [PMID: 22992069]

Djiogue, S.; Nwabo Kamdje, A.H.; Vecchio, L.; Kipanyula, M.J.; Farahna, M.; Aldebasi, Y.; Seke Etet, P.F. Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer, 2013, 20(1), R1-R17.
[http://dx.doi.org/10.1530/ERC-12-0324] [PMID: 23207292]

Kern, M.; Wells, J.A.; Stephens, J.M.; Elton, C.W.; Friedman, J.E.; Tapscott, E.B.; Pekala, P.H.; Dohm, G.L. Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level. Biochem. J., 1990, 270(2), 397-400.
[http://dx.doi.org/10.1042/bj2700397] [PMID: 2205203]

Grover-McKay, M.; Walsh, S.A.; Seftor, E.A.; Thomas, P.A.; Hendrix, M.J. Role for glucose transporter 1 protein in human breast cancer. Pathol. Oncol. Res., 1998, 4(2), 115-120.
[http://dx.doi.org/10.1007/BF02904704] [PMID: 9654596]

Acharya, S.; Xu, J.; Wang, X.; Jain, S.; Wang, H.; Zhang, Q.; Chang, C.C.; Bower, J.; Arun, B.; Seewaldt, V.; Yu, D. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. Am. J. Cancer Res., 2016, 6(5), 981-995.
[PMID: 27293993]

Calvo, M.B.; Figueroa, A.; Pulido, E.G.; Campelo, R.G.; Aparicio, L.A. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol., 2010, 2010, 205357.
[http://dx.doi.org/10.1155/2010/205357] [PMID: 20706540]

Alvino, C.L.; Ong, S.C.; McNeil, K.A.; Delaine, C.; Booker, G.W.; Wallace, J.C.; Forbes, B.E. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One, 2011, 6(11), e27488.
[http://dx.doi.org/10.1371/journal.pone.0027488] [PMID: 22140443]

Tan, B.X.; Yao, W.X.; Ge, J.; Peng, X.C.; Du, X.B.; Zhang, R.; Yao, B.; Xie, K.; Li, L.H.; Dong, H.; Gao, F.; Zhao, F.; Hou, J.M.; Su, J.M.; Liu, J.Y. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer, 2011, 117(22), 5103-5111.
[http://dx.doi.org/10.1002/cncr.26151] [PMID: 21523768]

Tzivion, G.; Dobson, M.; Ramakrishnan, G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta, 2011, 1813(11), 1938-1945.
[http://dx.doi.org/10.1016/j.bbamcr.2011.06.002] [PMID: 21708191]

Mu, N.; Zhu, Y.; Wang, Y.; Zhang, H.; Xue, F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol. Oncol., 2012, 125(3), 751-757.
[http://dx.doi.org/10.1016/j.ygyno.2012.03.032] [PMID: 22449736]

Bai, H.; Kang, P.; Tatar, M. Drosophila insulin-like peptide-6 (dilp6) expression from fat body extends lifespan and represses secretion of Drosophila insulin-like peptide-2 from the brain. Aging Cell, 2012, 11(6), 978-985.
[http://dx.doi.org/10.1111/acel.12000] [PMID: 22935001]

Bolukbasi, E.; Vass, S.; Cobbe, N.; Nelson, B.; Simossis, V.; Dunbar, D.R.; Heck, M.M. Drosophila poly suggests a novel role for the Elongator complex in insulin receptor-target of rapamycin signalling. Open Biol., 2012, 2(1), 110031.
[http://dx.doi.org/10.1098/rsob.110031] [PMID: 22645656]

Nunez, N.P.; Oh, W.J.; Rozenberg, J.; Perella, C.; Anver, M.; Barrett, J.C.; Perkins, S.N.; Berrigan, D.; Moitra, J.; Varticovski, L.; Hursting, S.D.; Vinson, C. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res., 2006, 66(10), 5469-5476.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-4102] [PMID: 16707476]

Dool, C.J.; Mashhedi, H.; Zakikhani, M.; David, S.; Zhao, Y.; Birman, E.; Carboni, J.M.; Gottardis, M.; Blouin, M.J.; Pollak, M. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr. Relat. Cancer, 2011, 18(6), 699-709.
[http://dx.doi.org/10.1530/ERC-11-0136] [PMID: 21946410]

Faria, A.M.; Almeida, M.Q. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol. Cell. Endocrinol., 2012, 351(1), 52-57.
[http://dx.doi.org/10.1016/j.mce.2011.09.040] [PMID: 22019901]

Ferguson, R.D.; Novosyadlyy, R.; Fierz, Y.; Alikhani, N.; Sun, H.; Yakar, S.; Leroith, D. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res., 2012, 14(1), R8.
[http://dx.doi.org/10.1186/bcr3089] [PMID: 22226054]

Gallagher, E.J.; Fierz, Y.; Vijayakumar, A.; Haddad, N.; Yakar, S.; LeRoith, D. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene, 2012, 31(27), 3213-3222.
[http://dx.doi.org/10.1038/onc.2011.495] [PMID: 22037215]

Fleming, H.E.; Janzen, V.; Lo Celso, C.; Guo, J.; Leahy, K.M.; Kronenberg, H.M.; Scadden, D.T. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell, 2008, 2(3), 274-283.
[http://dx.doi.org/10.1016/j.stem.2008.01.003] [PMID: 18371452]

Ashihara, E.; Kawata, E.; Nakagawa, Y.; Shimazaski, C.; Kuroda, J.; Taniguchi, K.; Uchiyama, H.; Tanaka, R.; Yokota, A.; Takeuchi, M.; Kamitsuji, Y.; Inaba, T.; Taniwaki, M.; Kimura, S.; Maekawa, T. β-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin. Cancer Res., 2009, 15(8), 2731-2738.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1350] [PMID: 19351774]

Rinderknecht, E.; Humbel, R.E. Primary structure of human insulin-like growth factor II. FEBS Lett., 1978, 89(2), 283-286.
[http://dx.doi.org/10.1016/0014-5793(78)80237-3] [PMID: 658418]

Blundell, T.L.; Bedarkar, S.; Rinderknecht, E.; Humbel, R.E. Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding. Proc. Natl. Acad. Sci. USA, 1978, 75(1), 180-184.
[http://dx.doi.org/10.1073/pnas.75.1.180] [PMID: 272633]

Sajid, W.; Kulahin, N.; Schluckebier, G.; Ribel, U.; Henderson, H.R.; Tatar, M.; Hansen, B.F.; Svendsen, A.M.; Kiselyov, V.V.; Nørgaard, P.; Wahlund, P.O.; Brandt, J.; Kohanski, R.A.; Andersen, A.S.; De Meyts, P. Structural and biological properties of the Drosophila insulin-like peptide 5 show evolutionary conservation. J. Biol. Chem., 2011, 286(1), 661-673.
[http://dx.doi.org/10.1074/jbc.M110.156018] [PMID: 20974844]

Pierre Eugene, C.; Pagesy, P.; Nguyen, TT.; Neuille, M.; Tschank, G.; Tennagels, N.; Hampe, C.; Issad, T. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One, 2012, 7, 41992.
[http://dx.doi.org/10.1371/journal.pone.0041992]

Jackson, J.G.; Zhang, X.; Yoneda, T.; Yee, D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene, 2001, 20(50), 7318-7325.
[http://dx.doi.org/10.1038/sj.onc.1204920] [PMID: 11704861]

Campagnoli, C.; Biglia, N.; Belforte, P.; Botta, D.; Pedrini, E.; Sismondi, P. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. Eur. J. Gynaecol. Oncol., 1992, 13(2), 139-154.
[PMID: 1587291]

Byrne, C.; Colditz, G.A.; Willett, W.C.; Speizer, F.E.; Pollak, M.; Hankinson, S.E. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res., 2000, 60(14), 3744-3748.
[PMID: 10919644]

Duggan, C.; Wang, C.Y.; Neuhouser, M.L.; Xiao, L.; Smith, A.W.; Reding, K.W.; Baumgartner, R.N.; Baumgartner, K.B.; Bernstein, L.; Ballard-Barbash, R.; McTiernan, A. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int. J. Cancer, 2013, 132(5), 1191-1200.
[http://dx.doi.org/10.1002/ijc.27753] [PMID: 22847383]

Izzo, L.; Meggiorini, M.L.; Nofroni, I.; Pala, A.; De Felice, C.; Meloni, P.; Simari, T.; Izzo, S.; Pugliese, F.; Impara, L.; Merlini, G.; Di Cello, P.; Cipolla, V.; Forcione, A.R.; Paliotta, A.; Domenici, L.; Bolognese, A. Insulin-like growth factor-I (IGF-1), IGF-binding protein-3 (IGFBP-3) and mammographic features. G. Chir., 2012, 33(5), 153-162.
[PMID: 22709450]

Rosen, N.; Yee, D.; Lippman, M.E.; Paik, S.; Cullen, K.J. Insulin- like growth factors in human breast cancer. Breast Cancer Res. Treat., 1991, 18(Suppl. 1), S55-S62.
[http://dx.doi.org/10.1007/BF02633529] [PMID: 1651793]

Bruning, P.F.; Van Doorn, J.; Bonfrèr, J.M.; Van Noord, P.A.; Korse, C.M.; Linders, T.C.; Hart, A.A. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre- menopausal breast cancer. Int. J. Cancer, 1995, 62(3), 266-270.
[http://dx.doi.org/10.1002/ijc.2910620306] [PMID: 7543079]

Pasanisi, P.; Bruno, E.; Venturelli, E.; Manoukian, S.; Barile, M.; Peissel, B.; De Giacomi, C.; Bonanni, B.; Berrino, J.; Berrino, F. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Fam. Cancer, 2011, 10(3), 521-528.
[http://dx.doi.org/10.1007/s10689-011-9437-y] [PMID: 21455766]

Al-Delaimy, W.K.; Flatt, S.W.; Natarajan, L.; Laughlin, G.A.; Rock, C.L.; Gold, E.B.; Caan, B.J.; Parker, B.A.; Pierce, J.P. IGF1 and risk of additional breast cancer in the WHEL study. Endocr. Relat. Cancer, 2011, 18(2), 235-244.
[PMID: 21263044]

Trinconi, A.F.; Filassi, J.R.; Soares, J.M., Jr; Baracat, E.C. Evaluation of the insulin-like growth factors (IGF) IGF-I and IGF binding protein 3 in patients at high risk for breast cancer. Fertil. Steril., 2011, 95(8), 2753-2755.
[http://dx.doi.org/10.1016/j.fertnstert.2011.02.014] [PMID: 21392749]

Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene, 2011, 30(10), 1174-1182.
[http://dx.doi.org/10.1038/onc.2010.483] [PMID: 21102522]

Byers, T.; Sedjo, R.L. Does intentional weight loss reduce cancer risk? Diabetes Obes. Metab., 2011, 13(12), 1063-1072.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01464.x] [PMID: 21733057]

Sakurai, T.; Kudo, M. Signaling pathways governing tumor angiogenesis. Oncology, 2011, 81(Suppl. 1), 24-29.
[http://dx.doi.org/10.1159/000333256] [PMID: 22212932]

Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer, 2012, 12(3), 159-169.
[http://dx.doi.org/10.1038/nrc3215] [PMID: 22337149]

Seke Etet, P.F.; Vecchio, L.; Nwabo Kamdje, A.H. Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cell. Signal., 2012, 24(7), 1433-1443.
[http://dx.doi.org/10.1016/j.cellsig.2012.03.008] [PMID: 22446006]

Nagamani, M.; Stuart, C.A. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am. J. Obstet. Gynecol., 1998, 179(1), 6-12.
[http://dx.doi.org/10.1016/S0002-9378(98)70244-3] [PMID: 9704758]

Kalme, T.; Koistinen, H.; Loukovaara, M.; Koistinen, R.; Leinonen, P. Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells. J. Steroid Biochem. Mol. Biol., 2003, 86(2), 197-200.
[http://dx.doi.org/10.1016/S0960-0760(03)00268-1] [PMID: 14568572]

Furukawa, J.; Wraight, C.J.; Freier, S.M.; Peralta, E.; Atley, L.M.; Monia, B.P.; Gleave, M.E.; Cox, M.E. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate, 2010, 70(2), 206-218.
[http://dx.doi.org/10.1002/pros.21054] [PMID: 19790231]

Kim, J.S.; Kim, E.S.; Liu, D.; Lee, J.J.; Solis, L.; Behrens, C.; Lippman, S.M.; Hong, W.K.; Wistuba, I.I.; Lee, H.Y. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer, 2012, 118(9), 2454-2465.
[http://dx.doi.org/10.1002/cncr.26492] [PMID: 21952750]

Chappell, S.A.; Walsh, T.; Walker, R.A.; Shaw, J.A. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br. J. Cancer, 1997, 76(12), 1558-1561.
[http://dx.doi.org/10.1038/bjc.1997.596] [PMID: 9413941]

Cheng, I.; Stram, D.O.; Burtt, N.P.; Gianniny, L.; Garcia, R.R.; Pooler, L.; Henderson, B.E.; Le Marchand, L.; Haiman, C.A. IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev., 2009, 18(6), 1922-1924.
[http://dx.doi.org/10.1158/1055-9965.EPI-09-0253] [PMID: 19435860]

Singer, C.; Rasmussen, A.; Smith, H.S.; Lippman, M.E.; Lynch, H.T.; Cullen, K.J. Malignant breast epithelium selects for insulin- like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res., 1995, 55(11), 2448-2454.
[PMID: 7757999]

Schiller, H.B.; Szekeres, A.; Binder, B.R.; Stockinger, H.; Leksa, V. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol. Biol. Cell, 2009, 20(3), 745-756.
[http://dx.doi.org/10.1091/mbc.e08-06-0569] [PMID: 19037107]

Pepper, M.S.; Vassalli, J.D.; Montesano, R.; Orci, L. Urokinase- type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol., 1987, 105(6 Pt 1), 2535-2541.
[http://dx.doi.org/10.1083/jcb.105.6.2535] [PMID: 3121633]

Takano, S.; Gately, S.; Neville, M.E.; Herblin, W.F.; Gross, J.L.; Engelhard, H.; Perricone, M.; Eidsvoog, K.; Brem, S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res., 1994, 54(10), 2654-2660.
[PMID: 7513254]

Leksa, V.; Loewe, R.; Binder, B.; Schiller, H.B.; Eckerstorfer, P.; Forster, F.; Soler-Cardona, A.; Ondrovicová, G.; Kutejová, E.; Steinhuber, E.; Breuss, J.; Drach, J.; Petzelbauer, P.; Binder, B.R.; Stockinger, H. Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation. Circ. Res., 2011, 108(6), 676-685.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.234732] [PMID: 21273553]

Sonne, D.P.; Engstrøm, T.; Treiman, M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept., 2008, 146(1-3), 243-249.
[http://dx.doi.org/10.1016/j.regpep.2007.10.001] [PMID: 17976835]

Drucker, D.J. Glucagon-like peptides. Diabetes, 1998, 47(2), 159-169.
[http://dx.doi.org/10.2337/diab.47.2.159] [PMID: 9519708]

Drucker, D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care, 2003, 26(10), 2929-2940.
[http://dx.doi.org/10.2337/diacare.26.10.2929] [PMID: 14514604]

Deacon, C.F.; Nauck, M.A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44(9), 1126-1131.
[http://dx.doi.org/10.2337/diab.44.9.1126] [PMID: 7657039]

Deacon, C.F.; Wamberg, S.; Bie, P.; Hughes, T.E.; Holst, J.J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol., 2002, 172(2), 355-362.
[http://dx.doi.org/10.1677/joe.0.1720355] [PMID: 11834453]

Dardevet, D.; Moore, M.C.; Neal, D.; DiCostanzo, C.A.; Snead, W.; Cherrington, A.D. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am. J. Physiol. Endocrinol. Metab., 2004, 287(1), E75-E81.
[http://dx.doi.org/10.1152/ajpendo.00035.2004] [PMID: 15026303]

Sancho, V.; Trigo, M.V.; González, N.; Valverde, I.; Malaisse, W.J.; Villanueva-Peñacarrillo, M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol., 2005, 35(1), 27-38.
[http://dx.doi.org/10.1677/jme.1.01747] [PMID: 16087719]

Pannacciulli, N.; Le, D.S.; Salbe, A.D.; Chen, K.; Reiman, E.M.; Tataranni, P.A.; Krakoff, J. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage, 2007, 35(2), 511-517.
[http://dx.doi.org/10.1016/j.neuroimage.2006.12.035] [PMID: 17317222]

Brubaker, P.L.; Drucker, D.J. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology, 2004, 145(6), 2653-2659.
[http://dx.doi.org/10.1210/en.2004-0015] [PMID: 15044356]

He, W.; Yu, S.; Wang, L.; He, M.; Cao, X.; Li, Y.; Xiao, H. Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. Mol. Cell. Endocrinol., 2016, 436, 240-249.
[http://dx.doi.org/10.1016/j.mce.2016.07.032] [PMID: 27496641]

Fidan-Yaylalı, G.; Dodurga, Y.; Seçme, M.; Elmas, L. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol., 2016, 37(2), 2647-2653.
[http://dx.doi.org/10.1007/s13277-015-4104-9] [PMID: 26399993]

Elashoff, M.; Matveyenko, A.V.; Gier, B.; Elashoff, R.; Butler, P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon- like peptide-1-based therapies. Gastroenterology, 2011, 141(1), 150-156.
[http://dx.doi.org/10.1053/j.gastro.2011.02.018] [PMID: 21334333]

Koehler, J.A.; Kain, T.; Drucker, D.J. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology, 2011, 152(9), 3362-3372.
[http://dx.doi.org/10.1210/en.2011-1201] [PMID: 21771884]

Ligumsky, H.; Wolf, I.; Israeli, S.; Haimsohn, M.; Ferber, S.; Karasik, A.; Kaufman, B.; Rubinek, T. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res. Treat., 2012, 132(2), 449-461.
[http://dx.doi.org/10.1007/s10549-011-1585-0] [PMID: 21638053]

Nomiyama, T.; Kawanami, T.; Irie, S.; Hamaguchi, Y.; Terawaki, Y.; Murase, K.; Tsutsumi, Y.; Nagaishi, R.; Tanabe, M.; Morinaga, H.; Tanaka, T.; Mizoguchi, M.; Nabeshima, K.; Tanaka, M.; Yanase, T. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes, 2014, 63(11), 3891-3905.
[http://dx.doi.org/10.2337/db13-1169] [PMID: 24879833]

Honors, M.A.; Kinzig, K.P. Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Horm. Cancer, 2014, 5(1), 33-41.
[http://dx.doi.org/10.1007/s12672-013-0163-9] [PMID: 24101584]

Evans, W.J.; Morley, J.E.; Argilés, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W.E.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Rossi Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; Wolfe, R.; Anker, S.D. Cachexia: a new definition. Clin. Nutr., 2008, 27(6), 793-799.
[http://dx.doi.org/10.1016/j.clnu.2008.06.013] [PMID: 18718696]

Gordon, J.N.; Green, S.R.; Goggin, P.M. Cancer cachexia. QJM, 2005, 98(11), 779-788.
[http://dx.doi.org/10.1093/qjmed/hci127] [PMID: 16214835]

Ovesen, L.; Allingstrup, L.; Hannibal, J.; Mortensen, E.L.; Hansen, O.P. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J. Clin. Oncol., 1993, 11(10), 2043-2049.
[http://dx.doi.org/10.1200/JCO.1993.11.10.2043] [PMID: 8410128]

Ovesen, L.; Hannibal, J.; Mortensen, E.L. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr. Cancer, 1993, 19(2), 159-167.
[http://dx.doi.org/10.1080/01635589309514246] [PMID: 8502586]

Ovesen, L.F.; Hannibal, J.G.; Sørensen, M.; Allingstrup, L. Fødeindtagelse, appetitnedsaettende symptomer og kemosensorisk taerskel hos cancerpatienter i kemoterapeutisk behandling. Ugeskr. Laeger, 1993, 155(11), 793-796. [Food intake, depressed appetite and chemosensory threshold in patients with cancer during chemotherapy].
[PMID: 8460430]

Matthys, P.; Billiau, A. Cytokines and cachexia. Nutrition, 1997, 13(9), 763-770.
[http://dx.doi.org/10.1016/S0899-9007(97)00185-8] [PMID: 9290087]

Nelson, D.; Ganss, R. Tumor growth or regression: powered by inflammation. J. Leukoc. Biol., 2006, 80(4), 685-690.
[http://dx.doi.org/10.1189/jlb.1105646] [PMID: 16864602]

He, L.; Law, P.T.Y.; Wong, C.K.; Chan, J.C.N.; Chan, P.K.S. Exendin-4 exhibits enhanced anti-tumor effects in diabetic mice. Sci. Rep., 2017, 7(1), 1791.
[http://dx.doi.org/10.1038/s41598-017-01952-5] [PMID: 28496193]

Koehler, J.A.; Drucker, D.J. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes, 2006, 55(5), 1369-1379.
[http://dx.doi.org/10.2337/db05-1145] [PMID: 16644694]

Iwaya, C.; Nomiyama, T.; Komatsu, S.; Kawanami, T.; Tsutsumi, Y.; Hamaguchi, Y.; Horikawa, T.; Yoshinaga, Y.; Yamashita, S.; Tanaka, T.; Terawaki, Y.; Tanabe, M.; Nabeshima, K.; Iwasaki, A.; Yanase, T. Exendin-4, a Glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-κB activation. Endocrinology, 2017, 158(12), 4218-4232.
[http://dx.doi.org/10.1210/en.2017-00461] [PMID: 29045658]

Ling, J.; Kumar, R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett., 2012, 322(2), 119-126.
[http://dx.doi.org/10.1016/j.canlet.2012.02.033] [PMID: 22433713]

Kothare, P.A.; Linnebjerg, H.; Isaka, Y.; Uenaka, K.; Yamamura, A.; Yeo, K.P.; de la Peña, A.; Teng, C.H.; Mace, K.; Fineman, M.; Shigeta, H.; Sakata, Y.; Irie, S. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J. Clin. Pharmacol., 2008, 48(12), 1389-1399.
[http://dx.doi.org/10.1177/0091270008323750] [PMID: 19047364]

Lin, E.; Garmo, H.; Van Hemelrijck, M.; Adolfsson, J.; Stattin, P.; Zethelius, B.; Crawley, D. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer, 2020, 20(1), 551.
[http://dx.doi.org/10.1186/s12885-020-07036-4] [PMID: 32539807]

He, W.; Li, J. Exendin-4 enhances radiation response of prostate cancer. Prostate, 2018, 78(15), 1125-1133.
[http://dx.doi.org/10.1002/pros.23687] [PMID: 30009503]

Funch, D.; Mortimer, K.; Li, L.; Norman, H.; Major-Pedersen, A.; Olsen, A.H.; Kaltoft, M.S.; Dore, D.D. Is there an association between liraglutide use and female breast cancer in a real-world setting? Diabetes Metab. Syndr. Obes., 2018, 11, 791-806.
[http://dx.doi.org/10.2147/DMSO.S171503] [PMID: 30538516]

Wilding, J.P.; Overgaard, R.V.; Jacobsen, L.V.; Jensen, C.B.; le Roux, C.W. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes. Metab., 2016, 18(5), 491-499.
[http://dx.doi.org/10.1111/dom.12639] [PMID: 26833744]

Caparrotta, T.M.; Templeton, J.B.; Clay, T.A.; Wild, S.H.; Reynolds, R.M.; Webb, D.J.; Colhoun, H.M. Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther., 2021, 12(4), 969-989.
[http://dx.doi.org/10.1007/s13300-021-01021-1] [PMID: 33635502]

Shadboorestan, A.; Tarighi, P.; Koosha, M.; Faghihi, H.; Ghahremani, M.H.; Montazeri, H. Growth promotion and increased atp-binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231. Drug Res. (Stuttg.), 2021, 71(6), 307-311.
[http://dx.doi.org/10.1055/a-1345-7890] [PMID: 33477190]

Mertens-Talcott, S.U.; Chintharlapalli, S.; Li, X.; Safe, S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res., 2007, 67(22), 11001-11011.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2416] [PMID: 18006846]

Tang, W.; Yu, F.; Yao, H.; Cui, X.; Jiao, Y.; Lin, L.; Chen, J.; Yin, D.; Song, E.; Liu, Q. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene, 2014, 33(20), 2629-2638.
[http://dx.doi.org/10.1038/onc.2013.214] [PMID: 23752185]

Fox, M.M.; Phoenix, K.N.; Kopsiaftis, S.G.; Claffey, K.P. AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes Cancer, 2013, 4(1-2), 3-14.
[http://dx.doi.org/10.1177/1947601913486346] [PMID: 23946867]

Zhao, X.B.; Ren, G.S. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(49), e5602.
[http://dx.doi.org/10.1097/MD.0000000000005602] [PMID: 27930583]

Frasca, F.; Pandini, G.; Sciacca, L.; Pezzino, V.; Squatrito, S.; Belfiore, A.; Vigneri, R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem., 2008, 114(1), 23-37.
[http://dx.doi.org/10.1080/13813450801969715] [PMID: 18465356]

Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368(9548), 1696-1705.
[http://dx.doi.org/10.1016/S0140-6736(06)69705-5] [PMID: 17098089]

Mizutani, S.; Sumi, S.; Narita, O.; Tomoda, Y. Purification and properties of human placental dipeptidyl peptidase IV. Nippon Sanka Fujinka Gakkai Zasshi, 1985, 37(5), 769-775.
[PMID: 2860191]

Heike, M.; Möbius, U.; Knuth, A.; Meuer, S.; Meyer zum Büschenfelde, K.H. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin. Exp. Immunol., 1988, 74(3), 431-434.
[PMID: 2466591]

Nemoto, E.; Sugawara, S.; Takada, H.; Shoji, S.; Horiuch, H. Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components. Infect. Immun., 1999, 67(12), 6225-6233.
[http://dx.doi.org/10.1128/IAI.67.12.6225-6233.1999] [PMID: 10569731]

Varona, A.; Blanco, L.; Perez, I.; Gil, J.; Irazusta, J.; López, J.I.; Candenas, M.L.; Pinto, F.M.; Larrinaga, G. Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer, 2010, 10, 193.
[http://dx.doi.org/10.1186/1471-2407-10-193] [PMID: 20459800]

Hanski, C.; Huhle, T.; Gossrau, R.; Reutter, W. Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp. Cell Res., 1988, 178(1), 64-72.
[http://dx.doi.org/10.1016/0014-4827(88)90378-3] [PMID: 2900773]

Piazza, G.A.; Callanan, H.M.; Mowery, J.; Hixson, D.C. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem. J., 1989, 262(1), 327-334.
[http://dx.doi.org/10.1042/bj2620327] [PMID: 2573346]

Chen, W.T.; Lee, C.C.; Goldstein, L.; Bernier, S.; Liu, C.H.; Lin, C.Y.; Yeh, Y.; Monsky, W.L.; Kelly, T.; Dai, M. Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res. Treat., 1994, 31(2-3), 217-226.
[http://dx.doi.org/10.1007/BF00666155] [PMID: 7881100]

Johnson, R.C.; Zhu, D.; Augustin-Voss, H.G.; Pauli, B.U. Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J. Cell Biol., 1993, 121(6), 1423-1432.
[http://dx.doi.org/10.1083/jcb.121.6.1423] [PMID: 8099589]

Cheng, H.C.; Abdel-Ghany, M.; Elble, R.C.; Pauli, B.U. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem., 1998, 273(37), 24207-24215.
[http://dx.doi.org/10.1074/jbc.273.37.24207] [PMID: 9727044]

Cheng, H.C.; Abdel-Ghany, M.; Zhang, S.; Pauli, B.U. Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin. Exp. Metastasis, 1999, 17(7), 609-615.
[http://dx.doi.org/10.1023/A:1006757525190] [PMID: 10845560]

Cheng, H.C.; Abdel-Ghany, M.; Pauli, B.U. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J. Biol. Chem., 2003, 278(27), 24600-24607.
[http://dx.doi.org/10.1074/jbc.M303424200] [PMID: 12716896]

Chang, Y.H.; Lee, S.H.; Liao, I.C.; Huang, S.H.; Cheng, H.C.; Liao, P.C. Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol. Cell. Proteomics, 2012, 11(11), 1320-1339.
[http://dx.doi.org/10.1074/mcp.M112.017384] [PMID: 22896658]

Hung, T.T.; Wu, J.Y.; Liu, J.F.; Cheng, H.C. Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion. FEBS J., 2009, 276(22), 6548-6559.
[http://dx.doi.org/10.1111/j.1742-4658.2009.07352.x] [PMID: 19804410]

Abdel-Ghany, M.; Cheng, H.; Levine, R.A.; Pauli, B.U. Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells. Invasion Metastasis, 1998, 18(1), 35-43.
[http://dx.doi.org/10.1159/000024497] [PMID: 10207249]

Choi, H.J.; Kim, J.Y.; Lim, S.C.; Kim, G.; Yun, H.J.; Choi, H.S. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br. J. Pharmacol., 2015, 172(21), 5096-5109.
[http://dx.doi.org/10.1111/bph.13274] [PMID: 26267432]

Lu, K.P.; Zhou, X.Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol., 2007, 8(11), 904-916.
[http://dx.doi.org/10.1038/nrm2261] [PMID: 17878917]

Liou, Y.C.; Zhou, X.Z.; Lu, K.P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem. Sci., 2011, 36(10), 501-514.
[http://dx.doi.org/10.1016/j.tibs.2011.07.001] [PMID: 21852138]

Wulf, G.M.; Ryo, A.; Wulf, G.G.; Lee, S.W.; Niu, T.; Petkova, V.; Lu, K.P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J., 2001, 20(13), 3459-3472.
[http://dx.doi.org/10.1093/emboj/20.13.3459] [PMID: 11432833]

Zheng, H.; You, H.; Zhou, X.Z.; Murray, S.A.; Uchida, T.; Wulf, G.; Gu, L.; Tang, X.; Lu, K.P.; Xiao, Z.X. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature, 2002, 419(6909), 849-853.
[http://dx.doi.org/10.1038/nature01116] [PMID: 12397361]

Ryo, A.; Suizu, F.; Yoshida, Y.; Perrem, K.; Liou, Y.C.; Wulf, G.; Rottapel, R.; Yamaoka, S.; Lu, K.P. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell, 2003, 12(6), 1413-1426.
[http://dx.doi.org/10.1016/S1097-2765(03)00490-8] [PMID: 14690596]

Fukuchi, M.; Fukai, Y.; Kimura, H.; Sohda, M.; Miyazaki, T.; Nakajima, M.; Masuda, N.; Tsukada, K.; Kato, H.; Kuwano, H. Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int. J. Oncol., 2006, 29(2), 329-334.
[http://dx.doi.org/10.3892/ijo.29.2.329] [PMID: 16820873]

Khanal, P.; Namgoong, G.M.; Kang, B.S.; Woo, E.R.; Choi, H.S. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol. Cancer Ther., 2010, 9(3), 606-616.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0560] [PMID: 20179161]

Kim, K.; Kim, G.; Kim, J.Y.; Yun, H.J.; Lim, S.C.; Choi, H.S. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis, 2014, 35(6), 1352-1361.
[http://dx.doi.org/10.1093/carcin/bgu044] [PMID: 24517997]

Russo, J.W.; Gao, C.; Bhasin, S.S.; Voznesensky, O.S.; Calagua, C.; Arai, S.; Nelson, P.S.; Montgomery, B.; Mostaghel, E.A.; Corey, E.; Taplin, M.E.; Ye, H.; Bhasin, M.; Balk, S.P. Downregulation of dipeptidyl peptidase 4 accelerates progression to castration-resistant prostate cancer. Cancer Res., 2018, 78(22), 6354-6362.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-0687] [PMID: 30242112]

Yang, F.; Takagaki, Y.; Yoshitomi, Y.; Ikeda, T.; Li, J.; Kitada, M.; Kumagai, A.; Kawakita, E.; Shi, S.; Kanasaki, K.; Koya, D. Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR Axis. Cancer Res., 2019, 79(4), 735-746.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-0620] [PMID: 30584072]

Shah, C.; Hong, Y.R.; Bishnoi, R.; Ali, A.; Skelton, W.P., IV; Dang, L.H.; Huo, J.; Dang, N.H. Impact of DPP4 inhibitors in survival of patients with prostate, pancreas, and breast cancer. Front. Oncol., 2020, 10, 405.
[http://dx.doi.org/10.3389/fonc.2020.00405] [PMID: 32296640]

Tseng, C.H. Sitagliptin may reduce breast cancer risk in women with type 2 diabetes. Clin. Breast Cancer, 2017, 17(3), 211-218.
[http://dx.doi.org/10.1016/j.clbc.2016.11.002] [PMID: 27986440]

Barreira da Silva, R.; Laird, M.E.; Yatim, N.; Fiette, L.; Ingersoll, M.A.; Albert, M.L. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol., 2015, 16(8), 850-858.
[http://dx.doi.org/10.1038/ni.3201] [PMID: 26075911]

Hollande, C.; Boussier, J.; Ziai, J.; Nozawa, T.; Bondet, V.; Phung, W.; Lu, B.; Duffy, D.; Paradis, V.; Mallet, V.; Eberl, G.; Sandoval, W.; Schartner, J.M.; Pol, S.; Barreira da Silva, R.; Albert, M.L. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol., 2019, 20(3), 257-264.
[http://dx.doi.org/10.1038/s41590-019-0321-5] [PMID: 30778250]

Vanheule, V.; Metzemaekers, M.; Janssens, R.; Struyf, S.; Proost, P. How post-translational modifications influence the biological activity of chemokines. Cytokine, 2018, 109, 29-51.
[http://dx.doi.org/10.1016/j.cyto.2018.02.026] [PMID: 29903573]

Lam, C.S.; Cheung, A.H.; Wong, S.K.; Wan, T.M.; Ng, L.; Chow, A.K.; Cheng, N.S.; Pak, R.C.; Li, H.S.; Man, J.H.; Yau, T.C.; Lo, O.S.; Poon, J.T.; Pang, R.W.; Law, W.L. Prognostic significance of CD26 in patients with colorectal cancer. PLoS One, 2014, 9(5), e98582.
[http://dx.doi.org/10.1371/journal.pone.0098582] [PMID: 24870408]

Liang, P.I.; Yeh, B.W.; Li, W.M.; Chan, T.C.; Chang, I.W.; Huang, C.N.; Li, C.C.; Ke, H.L.; Yeh, H.C.; Wu, W.J.; Li, C.F. DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness. Oncotarget, 2017, 8(2), 2995-3008.
[http://dx.doi.org/10.18632/oncotarget.13820] [PMID: 27936466]

Yamaguchi, U.; Nakayama, R.; Honda, K.; Ichikawa, H.; Hasegawa, T.; Shitashige, M.; Ono, M.; Shoji, A.; Sakuma, T.; Kuwabara, H.; Shimada, Y.; Sasako, M.; Shimoda, T.; Kawai, A.; Hirohashi, S.; Yamada, T. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J. Clin. Oncol., 2008, 26(25), 4100-4108.
[http://dx.doi.org/10.1200/JCO.2007.14.2331] [PMID: 18757323]

Nishina, S.; Yamauchi, A.; Kawaguchi, T.; Kaku, K.; Goto, M.; Sasaki, K.; Hara, Y.; Tomiyama, Y.; Kuribayashi, F.; Torimura, T.; Hino, K. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice. Cell. Mol. Gastroenterol. Hepatol., 2018, 7(1), 115-134.
[http://dx.doi.org/10.1016/j.jcmgh.2018.08.008] [PMID: 30510994]

Seyfried, T.N.; Shelton, L.M. Cancer as a metabolic disease. Nutr. Metab. (Lond.), 2010, 7, 7.
[http://dx.doi.org/10.1186/1743-7075-7-7] [PMID: 20181022]

Ward, P.S.; Thompson, C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell, 2012, 21(3), 297-308.
[http://dx.doi.org/10.1016/j.ccr.2012.02.014] [PMID: 22439925]

Gaude, E.; Frezza, C. Defects in mitochondrial metabolism and cancer. Cancer Metab., 2014, 2, 10.
[http://dx.doi.org/10.1186/2049-3002-2-10] [PMID: 25057353]

Apaijai, N.; Pintana, H.; Chattipakorn, S.C.; Chattipakorn, N. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br. J. Pharmacol., 2013, 169(5), 1048-1057.
[http://dx.doi.org/10.1111/bph.12176] [PMID: 23488656]

Abuelezz, S.A.; Hendawy, N.; Abdel Gawad, S. Alleviation of renal mitochondrial dysfunction and apoptosis underlies the protective effect of sitagliptin in gentamicin-induced nephrotoxicity. J. Pharm. Pharmacol., 2016, 68(4), 523-532.
[http://dx.doi.org/10.1111/jphp.12534] [PMID: 27019059]

Weng, G.; Zhou, B.; Liu, T.; Huang, Z.; Yang, H. Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1α/NRF1/TFAM. IUBMB Life, 2019, 71(10), 1515-1521.
[http://dx.doi.org/10.1002/iub.2076] [PMID: 31290617]

Li, Y.; Li, Y.; Li, D.; Li, K.; Quan, Z.; Wang, Z.; Sun, Z. Repositioning of hypoglycemic drug linagliptin for cancer treatment. Front. Pharmacol., 2020, 11, 187.
[http://dx.doi.org/10.3389/fphar.2020.00187] [PMID: 32194417]